Compugen Ltd., a clinical-stage therapeutic discovery and development company, is engaged in the research, development, and commercialization of therapeutic candidates and products in Israel, the United States, and Europe. The company is headquartered in Holon, Israel.
| Revenue (TTM) | $74.00M |
| Gross Profit (TTM) | $64.30M |
| EBITDA | $30.68M |
| Operating Margin | -339.60% |
| Return on Equity | 50.60% |
| Return on Assets | 15.50% |
| Revenue/Share (TTM) | $0.79 |
| Book Value | $0.94 |
| Price-to-Book | 2.51 |
| Price-to-Sales (TTM) | 2.51 |
| EV/Revenue | 1.491 |
| EV/EBITDA | 3.60 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 107.00% |
| Shares Outstanding | $94.72M |
| Float | $94.51M |
| % Insiders | 0.38% |
| % Institutions | 15.17% |
Volatility is currently expanding
HOLON, ISRAEL, Oct. 6, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI, today announced that management will participate in a fireside chat at the H.C.
Compugen NASDAQ: CGEN outlined the clinical rationale for its COM701 antibody in platinum-sensitive ovarian cancer and described an expansion of its AI-powered discovery platform into tumor-associated antigen, or TAA, research during a company update event.
Compugen Ltd. (CGEN) Discusses COM701 in Ovarian Cancer, MAIA Trial Preview, and UNIGEN Platform Advancements Transcript
HOLON, Israel, Sept. 8, 2026 /PRNewswire/ -- Compugen Ltd.
Compugen (CGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Here is how Compugen (CGEN) and Envoy Medical, Inc. (COCH) have performed compared to their sector so far this year.
Compugen has improved and now has a more forgiving runway into 2029. This should carry it through MAIA's interim analysis. In my view, MAIA remains the main value driver, which is why CGEN's runway materially improves its risk-reward profile. A positive randomized readout could help validate COM701, and it would be a win for CGEN's broader PVRIG approach.
Compugen Ltd. (CGEN) Q2 2026 Earnings Call Transcript
Compugen NASDAQ: CGEN said its second-quarter 2026 progress included continued enrollment in its MAIA-ovarian study of COM701, advancing partner-led programs with AstraZeneca and Gilead, and a cash runway projected to extend into 2029.
Compugen (CGEN) came out with a quarterly loss of $0.07 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.08 per share a year ago.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on CGEN and any ticker you trade — then tracks every position and per-strategy win rate.
